You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Molecular Testing Labs allegedly made payments to labs in exchange for Medicare and Tricare referrals between August 2014 and July 2015.
ACLA was critical of the report, saying it "fails to reflect market reality" and calling on Congress to intervene to prevent further cuts.
The effort is one of five being undertaken by MDIC's Clinical Diagnostic Program designed to expedite the regulatory process for clinical diagnostics.
The unique, test-specific PLA codes make it easier for insurers to identify tests and apply positive or negative coverage policies, billing experts say.
Newly announced changes will enable more hospital outreach laboratories to submit lab pricing data, but lab groups say more changes are needed.
The Tulsa, Oklahoma-based lab, which received its CLIA license in August, will run samples reimbursed by Medicare and state Medicaid agencies only.
Palmetto GBA issued final local coverage determination for the tissue-based, 31-gene expression test, which determines a patient’s risk for metastatic disease.
Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.